News NICE recommends cannabinoid med for severe epilepsy Global biopharma Jazz Pharmaceuticals’ Epidyolex/Epidiolex (cannabidiol), developed by GW Pharmaceuticals and now part of Jazz, has received
News Jazz breaks ground on $100m UK plant for cannabinoid drugs Jazz Pharma has started construction of a manufacturing facility in the UK that will be used to manufacture cannabinoid drugs from its recently
News NICE backs NHS funding for two cannabis-based drugs for firs... NICE has recommended two of GW Pharma's cannabis-based medicines, the first time that medicines derived from the plant have been recommended for NHS funding.
News GW launches cannabis-based epilepsy drug in US GW Pharmaceuticals is bullish about the company’s prospects following the launch of its cannabis-based medicine for a rare form of childhood epilepsy.
News UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face